GBA Presents: House of Gummy-!

vanzandt said:
Maybe Godzilla throws Greta from atop the Empire State building. :thumbsup:
More...



Oh Van it's about survivor guilt. I held tough to that little Japanese girl cries so hard. What did they do to that little girl to make her cry like that.

And then when the hero who was a coward as a kamakazi mans up and takes the special jet out.. There was a red handle that was to arm the bomb but i knew it was also an ejector seat.. I was right.

Good movie. Great CGI.
 
A small Canadian biotech with 3 employees. Yes please!

Xortx Therapeutics price target raised by $5 at Alliance Global Partners, » 08:29 XRTX


XORTX Therapeutics Inc. (XRTX)
NasdaqCM - NasdaqCM Delayed Price.
2.4900+0.2900(+13.18%)
At close: 03:59PM EST
2.3700-0.12(-4.82%)<------------------:caution:
Pre-Market:08:52AM EST

CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.

The positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported in Q1 2023 (the “Study”) characterized the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLO™. Results from the Study showed that XORLO™ was well tolerated by the 88 subjects who received the drug. There were no safety concerns during the testing of drug across the various dosing regimens used. Overall results were positive and showed: i) a substantial increase in the bioavailability of oxypurinol with the XORLO™ formulation platform; (ii) a substantially increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values. In simple terms, substantially increased early oral absorption of XORLO™, and increased circulating concentrations of oxypurinol necessary to inhibit production of uric acid across the desired therapeutic range and thereby slow down the advancements of CKD. Each of these results will provide key data to facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease due to ADPKD as well as other causes of CKD.

Description

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
 
Ted- Interesting turn of events at CCCS. I no longer am sure about a decline. Substantial Secondary done fairly close to the price-- and " upsized " which means they had a lot of takers.

Very diluting but in this day of high interest rates and difficulty borrowing this ' negative ' event likely will be seen as a game changer.
 
Traditional arms are also back in fashion, with BAE Systems (OTCPK:BAESY) announcing on Thursday that it would restart production of M777 howitzer parts for the U.S. Army. Putting it in perspective, the last order that took place was five years ago, but with output back online, BAE (OTCPK:BAESY) expects to ink new contracts for the artillery cannons given inquiries from more than eight countries.

It's not the only company going into overdrive. Thales is bringing back the Starstreak portable air-defense missile, while other firms like Raytheon (NYSE:RTX) struggle to ramp up production of the popular NASAMS, which helps protect crucial areas like the airspace over the White House.
 
  • AbbVie's (NYSE:ABBV) shares fell marginally following CVS Health's decision to exclude the pharmaceutical company's anti-inflammatory drug Humira from its major national commercial formularies on April 1, opting to cover biosimilars of the product instead. However, Humira will still be part of CVS' Choice and Standard Opt Out commercial formularies. Notably, AbbVie has committed to supplying a specific volume of Humira co-branded with CVS' new Cordavis biosimilar unit.
 
Boy I was sweating when I had the lowest S&P target on the street.

GBA is seldom but in that position. And then all these talking heads came out each with a higher S&P target, House after House after House: BAC, Morgan, Goldman...House of Gummy Held strong we didn't change our prediction to match everyone else and now suddenly everyone is saying we are going nowhere fast this year and that stoned guy in his underpants was right all along.
 
vanzandt said:
You might want to consider not chasing these high flyer's for now, and perhaps pick up a few domestic energy plays. Follow the money Stoney. Pretty sure I've covered the importance of sector rotation once or twice with you. ;)
More...
Nailed that one didn't we. Energy is up for 3 days in a row. Tech down 3 days in a row.

Stoney your Mobileye is getting hammered.
 
You must log in or register to reply here.
Back
Top